Top DOJ Atty Outlines Pharma Fraud Enforcement

Law360, New York (January 29, 2014, 7:03 PM EST) -- The U.S. Department of Justice's Civil Division chief on Wednesday delivered a stern message to pharmaceutical industry leaders about fraud enforcement, promising expanded use of intrusive oversight agreements and continued punishment of off-label marketing.

Assistant Attorney General Stuart F. Delery, speaking at the CBI Pharmaceutical Compliance Congress in Washington, D.C., outlined the aggressive posture while also vowing to be lenient with manufacturers when they're candid about potentially fraudulent activities, according to prepared remarks released by the DOJ.

One section of Delery’s speech focused on making so-called...
To view the full article, register now.